No Detail Found!

Assessment of the efficacy of topical antiandrogen; spironolactone in patients with androgenetic alopecia by dermoscopy

Author(s)
Ahmed M Soliman Department of Dermatology and Venereology, National Research Centre (NRC),33 El-Tahrir St., 12622 Dokki, Giza,Egypt
Sherief Mahdy Hussein Department of Dermatology and Venereology, National Research Centre (NRC),33 El-Tahrir St., 12622 Dokki, Giza,Egypt
Sameh Hosam Abd El-Alim Department of Pharmaceutical Technology, National Research Centre (NRC),33 El-Tahrir St., 12622 Dokki, Giza,Egypt
Ahmed Alaa Kassem Department of Pharmaceutical Technology, National Research Centre (NRC),33 El-Tahrir St., 12622 Dokki, Giza,Egypt
Hanaa Emam Department of Dermatology and Venereology, National Research Centre (NRC),33 El-Tahrir St., 12622 Dokki, Giza,Egypt
Hany Shehata Department of Dermatology and Venereology, National Research Centre (NRC),33 El-Tahrir St., 12622 Dokki, Giza,Egypt
Ahmad Abdelmaksood Rabie Department of Dermatology and Venereology, National Research Centre (NRC),33 El-Tahrir St., 12622 Dokki, Giza,Egypt
Hanan Farouk Aly Therapeutic Chemistry Department, National Research Centre (NRC), 33 El Tahrir St., 12622 Dokki, Giza, Egypt
Yasmin Bakr El Zawahry Department of Dermatology and Venereology, National Research Centre (NRC),33 El-Tahrir St., 12622 Dokki, Giza,Egypt
Abstract
Background Androgenetic Alopecia (AGA) is a non-scarring alopecia characterized by progressive miniaturization of hair follicles with a distinctive distribution in genetically prone males & females. Topical Spironolactone is commonly used as off-label anti-androgen for managment of AGA. Objective Assessing role of topical 1% spironolactone on hair thickness & count in patients with AGA using dermoscopy. Methods 26 patients (16 males and 10 females) with ages ranging from 26 to 59 years with a mean±SD of 42.77±6.62 received topical 1% spironolactone solution to apply on the scalp once daily for at least six months. All patients had positive family history. Dermoscopy was performed on fixed areas on the scalp. Images were taken with a digital camera that was connected to the dermoscope just before starting treatment and after 6 months continuous treatment. Results Significant increase in total terminal, terminal thick and total hair count in female patients along with a significant increase in total terminal, terminal thin, vellus and total hair count in male ones after treatment with topical 1% spironolactone were seen. However, thin and vellus hair in female and thick hair in male revealed no significant difference post spironolactone treatment. Conclusion Spironolactone is an effective & harmless treatment in both females & males with AGA.
Publication Details
Page(s) 493-501
DOI DOI not available
Published Journal: Journal of Pakistan Association of Dermatologists, Volume: 32, Issue: 3, Year: 2022

Request the full text from PASTIC

Keywords
androgenetic alopecia, Spironolactone, dermoscopy, antiandrogenic drugs
0

Citations

0

Downloads

37

Views